Sir Mortimer B. Davis - Jewish General Hospital

jgh.ca

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

61

Active

26

Phase 3

13

Total enrollment

21,092

Pipeline matrix

Showing 12 of 12 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Aprepitant1
Combination Therapy Arm1
Androgen deprivation therapy1
Leuprolide Acetate1
Goserelin Acetate1
Triptorelin1
Enzalutamide1
18F-fluorocholine PET/CT.1
OnabotulinumtoxinA1
Capecitabine1
Darolutamide1
Methoxyflurane anesthesia1

Next readouts

  • 2026-03-07
  • 2026-10-01
  • 2026-12
  • 2027-04
  • 2027-05-01
  • 2027-06-01
  • 2028-01-01
  • 2030-01
  • 2030-11

Top conditions

  • Prostate Cancer17
  • Erectile Dysfunction Following Radical Prostatectomy3
  • COVID-192
  • Cancer2
  • Post-Thrombotic Syndrome2
  • Head Neck Cancer2
  • Rectal Cancer2
  • Metastatic Prostate Cancer2

Frequently asked questions about Sir Mortimer B. Davis - Jewish General Hospital

How many clinical trials does Sir Mortimer B. Davis - Jewish General Hospital have on ClinicalTrials.gov?
Sir Mortimer B. Davis - Jewish General Hospital is listed as the lead sponsor on 61 clinical trials in ClinicalTrials.gov, 26 of which are currently active (recruiting, enrolling, or ongoing).
How many of Sir Mortimer B. Davis - Jewish General Hospital's trials are in Phase 3?
13 of Sir Mortimer B. Davis - Jewish General Hospital's trials are in Phase 3, spread across 12 active drug programs.
What therapeutic areas does Sir Mortimer B. Davis - Jewish General Hospital focus on?
Sir Mortimer B. Davis - Jewish General Hospital's most-studied conditions on ClinicalTrials.gov are Prostate Cancer, Erectile Dysfunction Following Radical Prostatectomy, COVID-19, Cancer, Post-Thrombotic Syndrome.
When are Sir Mortimer B. Davis - Jewish General Hospital's next clinical trial readouts?
Sir Mortimer B. Davis - Jewish General Hospital has 9 upcoming primary-completion readouts tracked here; the soonest is “Aggressive Smoking Cessation Trial (ASAP)”, expected around 2026-03-07.